Placental Blood Flow: New Hope for Detecting Fetal Heart Defects | MRI Study

Detecting fetal congenital heart disease (CHD) earlier could become more achievable thanks to a new understanding of placental function. Research published in February 2026 in Magnetic Resonance in Medicine suggests that measuring placental vascular reactivity (PLVR) – how well blood vessels in the placenta respond to changes in carbon dioxide levels – can facilitate identify pregnancies at higher risk for CHD.

What is Placental Vascular Reactivity?

The placenta is vital for delivering oxygen and nutrients to a developing fetus. PLVR refers to the placenta’s ability to adjust blood flow in response to fluctuations in the mother’s carbon dioxide levels. Researchers used BOLD MRI (blood-oxygen-level dependent magnetic resonance imaging) to measure this reactivity. BOLD MRI detects changes in blood oxygenation, providing a non-invasive way to assess how the placental blood vessels are functioning. Essentially, it’s a way to ‘watch’ the placenta work in real-time.

The Study Findings: CHD and PLVR

The study, led by researchers whose work appears in Magnetic Resonance in Medicine and reported on by Medical Xpress, involved 103 pregnant women. Thirty-one were carrying fetuses later diagnosed with CHD, whereas the remaining 72 had healthy fetuses. The researchers found that PLVR was significantly lower in pregnancies affected by CHD (0.024 ∆BOLD/mmhg CO2) compared to those with healthy fetuses (0.03 ∆BOLD/mmhg CO2). This suggests that the placentas in pregnancies with CHD may have impaired vascular function.

It’s crucial to note that the pregnant women in the CHD group were, on average, further along in their pregnancies (34 ± 2.9 weeks) than those in the non-CHD group (30.7 ± 4.9 weeks). This difference in gestational age is likely due to the typical timing of CHD diagnosis, which often occurs during routine prenatal screenings later in pregnancy. Researchers accounted for gestational age in their analysis, but it remains a factor to consider when interpreting the results.

Beyond CHD: The Role of Maternal Diabetes

The study too revealed a complex interaction between maternal diabetes and PLVR. The researchers found that diabetes appeared to have different effects on PLVR in pregnancies with CHD versus those without. This suggests that maternal health conditions can influence placental function in ways that are specific to the presence of fetal CHD. Further research is needed to fully understand these interactions.

What Does This Mean for Prenatal Care?

This research doesn’t mean that PLVR measurement will immediately become a standard part of prenatal care. However, it represents a promising step towards developing new, non-invasive methods for identifying pregnancies at risk for CHD. Currently, CHD is often diagnosed during routine ultrasound examinations, but these may not detect all cases, particularly milder forms of the condition. The study provides evidence corroborating previous histopathologic findings of impaired vascular integrity in CHD pregnancies.

The study authors emphasize that What we have is a novel characterization of placental dysfunction in CHD. The reduced PLVR observed in CHD pregnancies suggests impaired vascular integrity within the placenta. This finding aligns with previous studies that have examined placental tissue after birth and found structural abnormalities in cases of CHD.

Limitations and Future Research

As with any research study, there are limitations to consider. The sample size of 103 pregnant women is relatively small and the study population may not be representative of all pregnancies. The study also only examined PLVR at a single point in time during pregnancy. Future research should investigate how PLVR changes throughout gestation and whether it can be used to predict the severity of CHD. The researchers are currently investigating the association between PLVR and fetal/infant outcomes in CHD, as noted in the PubMed abstract of the study.

Understanding Congenital Heart Disease

Congenital heart disease encompasses a range of birth defects that affect the structure and function of the heart. These defects can range in severity from mild to life-threatening. According to the Centers for Disease Control and Prevention (CDC), about 1% of births in the United States are affected by CHD each year. Early diagnosis and treatment are crucial for improving outcomes for infants with CHD.

What Comes Next: Ongoing Investigation and Potential Applications

The research team is continuing to analyze the data collected in this study to explore the relationship between PLVR and various fetal and infant outcomes in CHD. This includes assessing whether PLVR can predict the need for interventions after birth, such as surgery or medication. Further studies are also planned to investigate the potential of PLVR as a screening tool for CHD in larger and more diverse populations. The ultimate goal is to develop a reliable and accessible method for identifying pregnancies at risk for CHD, allowing for earlier intervention and improved outcomes for affected infants.